1-(p-Nitrophenyl)-2-amino-1,3-propanediol | CAS:119-62-0

We serve 1-(p-Nitrophenyl)-2-amino-1,3-propanediol CAS:119-62-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-(p-Nitrophenyl)-2-amino-1,3-propanediol

Chemical Name:1-(p-Nitrophenyl)-2-amino-1,3-propanediol
CAS.NO:119-62-0
Synonyms:1-(p-Nitrophenyl)-2-amino-1,3-propanediol
 
Physical and Chemical Properties:
Density 1.41 g/cm3
Boiling Point 451.9ºC at 760 mmHg
Melting Point 163-165ºC
Molecular Formula C9H12N2O4
Molecular Weight 212.20300
Flash Point 227.1ºC
Vapour Pressure 5.92E-09mmHg at 25°C
Index of Refraction 1.63
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Chloramphenicol(CAS:56-75-7).



Contact us for information like 1-(p-Nitrophenyl)-2-amino-1,3-propanediol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(p-Nitrophenyl)-2-amino-1,3-propanediol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(p-Nitrophenyl)-2-amino-1,3-propanediol Use and application,1-(p-Nitrophenyl)-2-amino-1,3-propanediol technical grade,usp/ep/jp grade.


Related News: f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.D-Ornithine Monohydrochloride manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.2-Chloro-1-cyclopropyl-2-(2-fluorophenyl)ethanone supplier Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.4,4-Difluoropiperidine hydrochloride vendor Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.